Hanmi Pharmaceutical Gains GLP-1 Approval; Lilly Deal Fails
What happened
Hanmi Pharmaceutical secured approval for its homegrown GLP-1 obesity drug in South Korea. Separately, a technology evaluation between Peptron and Eli Lilly concluded without a follow-on commercialization deal, causing Peptron's shares to plunge nearly 30%.
From edaily.co.kr
Why it matters
Hanmi Pharmaceutical's approval introduces a new competitor to the GLP-1 obesity drug market. The failure of the evaluation between Peptron and Eli Lilly removes a potential revenue stream for Eli Lilly.
From edaily.co.kr
Who's involved
- Hanmi PharmaceuticalWon approval for South Korea’s first homegrown GLP-1 obesity drug.
- Eli Lilly and CompanyWas involved in the technology evaluation that ended without a commercialization deal.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
May lose potential revenue from the failed technology evaluation with Peptron.
Keep exploring
The entities involved
-
Hanmi Pharmaceutical
South Korean pharmaceutical company
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.